Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 2012, 08:04 AM   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this
Labels: AEZS, Analysts New Coverage, Market News

Related Stocks

Chart Stock Name Last Change Volume 
  AEZS 2.18 -0.02 (0.91%) 226,800 

  Be the first to like this.
 


 

3284  4065  759  407 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 OAS 8.33-1.73 
 SPY 266.78+0.47 
 BAC 29.32+0.38 
 XLF 28.22+0.28 
 GE 17.91+0.26 
 F 12.60+0.02 
 EEM 45.86-0.31 
 T 38.10+1.20 
 UGAZ 5.80-0.79 
 VRX 21.87+1.32 
Partners & Brokers